- Home
- DVAX vs SLDP Comparison
DVAX vs SLDP Comparison
Compare DVAX & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- SLDP
- Stock Information
- Founded
- DVAX 1996
- SLDP 2011
- Country
- DVAX United States
- SLDP United States
- Employees
- DVAX N/A
- SLDP N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- SLDP Electrical Products
- Sector
- DVAX Health Care
- SLDP Energy
- Exchange
- DVAX Nasdaq
- SLDP Nasdaq
- Market Cap
- DVAX 1.2B
- SLDP 1.3B
- IPO Year
- DVAX 2004
- SLDP N/A
- Fundamental
- Price
- DVAX $11.21
- SLDP $6.08
- Analyst Decision
- DVAX Buy
- SLDP Strong Buy
- Analyst Count
- DVAX 4
- SLDP 1
- Target Price
- DVAX $26.50
- SLDP $7.00
- AVG Volume (30 Days)
- DVAX 1.7M
- SLDP 16.7M
- Earning Date
- DVAX 11-05-2025
- SLDP 11-04-2025
- Dividend Yield
- DVAX N/A
- SLDP N/A
- EPS Growth
- DVAX N/A
- SLDP N/A
- EPS
- DVAX N/A
- SLDP N/A
- Revenue
- DVAX $330,514,000.00
- SLDP $19,802,000.00
- Revenue This Year
- DVAX $23.23
- SLDP $27.38
- Revenue Next Year
- DVAX $16.57
- SLDP $37.97
- P/E Ratio
- DVAX N/A
- SLDP N/A
- Revenue Growth
- DVAX 26.73
- SLDP 9.85
- 52 Week Low
- DVAX $9.20
- SLDP $0.68
- 52 Week High
- DVAX $14.63
- SLDP $8.86
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- SLDP 49.66
- Support Level
- DVAX $10.97
- SLDP $5.58
- Resistance Level
- DVAX $11.43
- SLDP $8.02
- Average True Range (ATR)
- DVAX 0.36
- SLDP 0.88
- MACD
- DVAX 0.07
- SLDP -0.12
- Stochastic Oscillator
- DVAX 86.42
- SLDP 23.97
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.